Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 15

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 15
---
 reported
sale price of our common stock on the Nasdaq Capital Market on October 28, 2025, for aggregate gross proceeds of $1,750,000, and after
deducting commissions and estimated offering expenses payable by us, new investors in this offering will experience immediate dilution
of $0.44 per share, representing the difference between the assumed public offering price and our as adjusted pro forma net tangible book
value per share after giving effect to this offering. See “Dilution” for a more detailed discussion of the dilution you would
if you purchase common stock in this offering.

You may experience future dilution as a result of future equity offerings or sales.

In order to raise additional capital, we may in
the future offer additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices
that may not be the same as the price per share in this offering. The price per share at which we sell additional shares of our common
stock, or securities convertible or exchangeable into common stock, in future transactions may be lower than the price per share paid
by investors in this offering.

On October 10, 2025, we entered into the Securities
Purchase Agreement pursuant to which the Company sold and issued in the Private Placement 744,340 shares of common stock (or prefunded
warrants in lieu thereof) and warrants to purchase an aggregate of up to 1,488,680 shares of common stock. The Private Placement closed
on October 15, 2025. In connection with the Private Placement, we granted certain registration rights to the purchasers, pursuant to which,
among other things, we will prepare and file a registration statement with the SEC to register for resale the shares of common stock,
prefunded warrants and warrants within 30 days of the closing date of the Private Placement. Once the registration statement is
effective, these shares may be resold into the public market. These sales, or the anticipation that such sales may occur, may have a negative
impact on the market price of our common stock.

<div align='center'>S-9</div>

Our management will have broad discretion in the use of the net proceeds from this offering and may not use them effectively.

Our management will have broad discretion in the
application of the net proceeds from this offering and our stockholders will not have the opportunity as part of their investment decisions
to assess whether the net proceeds are being used appropriately. You may not agree with our decisions